Common Clinical Practice for Opioid-Induced Constipation: A Physician Survey

References

• Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006. 23(3):229–235.
   PubMedGoogle Scholar
• Drewes AM, Munkholm P, Simrén M, et al. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Scand J Pain. 2016;11:111–122.
   PubMedGoogle Scholar
• Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22(4):e96.
   Web of Science ®Google Scholar
• Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 5(3):137–144.
   PubMedGoogle Scholar
• Troberg K, Håkansson A, Dahlman D. Self-rated physical health and unmet healthcare needs among swedish patients in opioid substitution treatment. J Addict. 2019;2019:7942145.
   Google Scholar
• Veiga DR, Mendonça L, Sampaio R, Lopes JC, Azevedo LF. Incidence and health related quality of life of opioid-induced constipation in chronic noncancer pain patients: a prospective multicentre cohort study. Pain Res Treat. 2018;2018:5704627.
   Web of Science ®Google Scholar
• Sizar O, Gea R, Gupta M. Opioid Induced Constipation. StatPearls; 2021. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29630236. Accessed July 6, 2021.
   Google Scholar
• Andresen V, Banerji V, Hall G, Lass A, Emmanuel AV. The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries. United Eur Gastroenterol J. 2018;6(8):1254–1266.
   PubMed Web of Science ®Google Scholar
• Ducrotté P, Milce J, Soufflet C, Fabry C. Prevalence and clinical features of opioid-induced constipation in the general population: a French study of 15,000 individuals. United Eur Gastroenterol J. 2017;5(4):588–600.
   Web of Science ®Google Scholar
• Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Alimentary Pharmacol Ther. 2008;27(12):1224–1232. doi:10.1111/j.1365-2036.2008.03689.x
   Web of Science ®Google Scholar
• Brenner DM, Stern E, Cash BD. Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep. 2017;19(3):12.
   Google Scholar
• Alvaro D, Caraceni AT, Coluzzi F, et al. What to do and what not to do in the management of opioid-induced constipation: a choosing wisely report. Pain Ther. 2020;9(2):657–667.
   Web of Science ®Google Scholar
• Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: european expert consensus statement. United Eur Gastroenterol J. 2019;7(1):7–20.
   PubMed Web of Science ®Google Scholar
• Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–367.
   PubMed Web of Science ®Google Scholar
• Crockett S, Greer KB, Sultan S. (OIC) Guideline. Gastroenterology. 2019;156(1):228.
   Web of Science ®Google Scholar
• Crockett SD, Greer KB, Heidelbaugh JJ, et al. American gastroenterological association institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218–226.
   PubMed Web of Science ®Google Scholar
• Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017;18(10):1837–1863.
   PubMed Web of Science ®Google Scholar
• Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol. 2015;49(1):9–16.
   PubMed Web of Science ®Google Scholar
• Cosci F. “Bowel obsession syndrome” in a patient with chronic constipation. Gen Hosp Psychiatry. 2013;35(4):451.e1–3.
   Web of Science ®Google Scholar
• Towers AL, Burgio KL, Locher JL, Merkel IS, Safaeian M, Wald A. Constipation in the elderly: influence of dietary, psychological, and physiological factors. J Am Geriatr Soc. 1994;42(7):701–706.
   PubMed Web of Science ®Google Scholar
• Simren M, Palsson OS, Whitehead WE. Update on Rome IV criteria for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep. 2017;19(4):15.
   PubMedGoogle Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–68.
   PubMed Web of Science ®Google Scholar
• Musazzi UM, Rocco P, Brunelli C, Bisaglia L, Caraceni A, Minghetti P. Do laws impact opioids consumption? A breakpoint analysis based on Italian sales data. J Pain Res. 2018;11:1665–1672.
   Web of Science ®Google Scholar
• J V P, Christo PJ, LeQuang JA, Magnusson P. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety. Drug Des Devel Ther. 2020;14:1009–1025.
   Web of Science ®Google Scholar
• AIFA. RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO Rizmoic. 2021. Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_005017_047626_RCP.pdf&retry=0&sys=m0b1l3. Accessed July 6, 2021.
   Google Scholar
• AIFA. RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO Moventig; 2019.
   Google Scholar
• Coluzzi F, Scerpa MS, Naldemedine PJ, New A. Option for OIBD. J Pain Res. 2020;13:1209–1222.
   Web of Science ®Google Scholar
• Katakami N, Harada T, Murata T, et al. Randomized Phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859–3866.
   PubMed Web of Science ®Google Scholar
• Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol off J Eur Soc Med Oncol. 2018;29(6):1461–1467.
   Web of Science ®Google Scholar
• Saito Y, Yokota T, Arai M, Tada Y, Sumitani M. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies. J Pain Res. 2019;12:127–138.
   Web of Science ®Google Scholar
• Murphy JA, Sheridan EA. Evidence based review of pharmacotherapy for opioid-induced constipation in noncancer pain. Ann Pharmacother. 2018;52(4):370–379.
   PubMed Web of Science ®Google Scholar
• Cook S, Bell T, Sweeney C, Fehnel S, Hollis K. 883. J Pain. 2007;8(4):S71.
   Google Scholar
• Dueñas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016;9:457–467.
   PubMed Web of Science ®Google Scholar
• Keller MS, Jusufagic A, Spiegel BMR. Patient and provider differences in the treatment of opioid-induced constipation: a qualitative study. BMC Gastroenterol. 2019;19(1):182.
   Web of Science ®Google Scholar
• Frantsve LME, Kerns RD. Patient-provider interactions in the management of chronic pain: current findings within the context of shared medical decision making. Pain Med. 2007;8(1):25–35.
   PubMed Web of Science ®Google Scholar
• Lugoboni F, Mirijello A, Zamboni L, et al. High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments. Expert Opin Pharmacother. 2016;17(16):2135–2141.
   PubMed Web of Science ®Google Scholar